Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral ...

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...